The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy

Diabetes Research and Clinical Practice

Volumn 103, Issue 3, 2014, Pages

  Varadhan, Lakshminarayanan ^a   Humphreys, Tracy ^a   Walker, Adrian B ^a   Varughese, George I ^a  

^a UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST   (United Kingdom)

Author keywords

GLP 1 agonist; Retinopathy; Screening; Transient deterioration

Indexed keywords

GLP-1 AGONIST; RETINOPATHY; SCREENING; TRANSIENT DETERIORATION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; PEPTIDES; RECEPTORS, GLUCAGON; RISK FACTORS; VENOMS;

EID: 84898919428     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.12.041     Document Type: Article

References (20)

1. Vestgaard M., Ringholm L., Laugesen C.S., Rasmussen K.L., Damm P., Mathiesen E.R. Pregnancy-induced sight-threatening diabetic retinopathy in women with Type 1 diabetes. Diabet Med 2010, 27(April (4)):431-435.
2. Dahl-Jorgensen K., Brinchmann-Hansen O., Hanssen K.F., Sandvik L., Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed) 1985, 290(March (6471)):811-815.
3. Rasmussen K.L., Laugesen C.S., Ringholm L., Vestgaard M., Damm P., Mathiesen E.R. Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. Diabetologia 2010, 53(June (6)):1076-1083.
4. van Ballegooie E., Hooymans J.M., Timmerman Z., Reitsma W.D., Sluiter W.J., Schweitzer N.M., et al. Rapid deterioration of diabetic retinopathy during treatment with continuous subcutaneous insulin infusion. Diabetes Care 1984, 7(May-June (3)):236-242.
5. Varadhan L., Humphreys T., Walker A.B., Cheruvu C.V., Varughese G.I. Bariatric surgery and diabetic retinopathy: a pilot analysis. Obes Surg 2012, 22(March (3)):515-516.
6. Buse J.B., Klonoff D.C., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007, 29(January (1)):139-153.
7. Varadhan L., Humphreys T., Hariman C., Walker A.B., Varughese G.I. GLP-1 agonist treatment: implications for diabetic retinopathy screening. Diabetes Res Clin Pract 2011, 94(December (3)):e68-e71.
8. Taylor K., Gurney K., Han J., Pencek R., Walsh B., Trautmann M. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord 2011, 11(April):9.
9. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329(September (14)):977-986.
10. Lauritzen T., Frost-Larsen K., Larsen H.W., Deckert T. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet 1983, 1(January (8318)):200-204.
11. Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. The Kroc Collaborative Study Group. JAMA 1988, 260(July (1)):37-41.
12. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(October (15)):1577-1589.
13. Henricsson M., Nilsson A., Janzon L., Groop L. The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med 1997, 14(February (2)):123-131.
14. Reichard P., Britz A., Cars I., Nilsson B.Y., Sobocinsky-Olsson B., Rosenqvist U. The Stockholm Diabetes Intervention Study (SDIS): 18 months' results. Acta Med Scand 1988, 224(2):115-122.
15. Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 1998, 82(July (7)):725-730.
16. Henricsson M., Berntorp K., Fernlund P., Sundkvist G. Progression of retinopathy in insulin-treated type 2 diabetic patients. Diabetes Care 2002, 25(February (2)):381-385.
17. Dahl-Jorgensen K., Brinchmann-Hansen O., Hanssen K.F., Ganes T., Kierulf P., Smeland E., et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br Med J (Clin Res Ed) 1986, 293(November (6556)):1195-1199.
18. Brinchmann-Hansen O., Dahl-Jorgensen K., Sandvik L., Hanssen K.F. Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study. BMJ 1992, 304(January (6818)):19-22.
19. Agardh C.D., Eckert B., Agardh E. Irreversible progression of severe retinopathy in young type I insulin-dependent diabetes mellitus patients after improved metabolic control. J Diabetes Complications 1992, 6(April-June (2)):96-100.
20. Moskalets E., Galstyan G., Starostina E., Antsiferov M., Chantelau E. Association of blindness to intensification of glycemic control in insulin-dependent diabetes mellitus. J Diabetes Complications 1994, 8(January-March (1)):45-50.